CASE COMMENTS: UNILATERAL PRACTICES – UE – EXPLOITATIVE ABUSES – PHARMACEUTICAL SECTOR – EXCESSIVE PRICES – COMMITMENTS

Exploitative abuse: The European Commission initiates a market test of commitments proposed by a pharmaceutical company to address its competition concerns about possible excessive prices for anti-cancer drugs (Aspen)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. The Commission is launching a market test to gather the views of interested parties onAspen 's proposed commitments to address competition concerns relating to its pricing practices on a number of cancer drugs. Pending a comment on the substance of the case - the Commission is only at the stage of a market test and not a decision making the commitments binding (on the basis of Article 9 of Regulation 1/2003) - the purpose of this letter is to recall the nature of the case and to present the proposals for commitments made by Aspen Pharma and submitted by the Commission to a market test. The investigation launched by the European Commission in May 2017

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Côte d’Azur University, GREDEG (Nice)

Quotation

Frédéric Marty, Exploitative abuse: The European Commission initiates a market test of commitments proposed by a pharmaceutical company to address its competition concerns about possible excessive prices for anti-cancer drugs (Aspen), 14 July 2020, Concurrences N° 4-2020, Art. N° 97560, pp. 133-134

Visites 44

All reviews